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Abstract
Scabies remains one of the commonest of skin diseases seen in developing countries. Although its distribution is subject to a cycle of
infection, with peaks and troughs of disease prevalence, this periodicity is often less obvious in poor communities. Scabies is a condition
that affects families, particularly the most vulnerable; it also has the greatest impact on young children. Largely through the association
with secondary bacterial infection caused by group A streptococci and Staphylococcus aureus, the burden of disease is compounded by
nephritis, rheumatic fever and sepsis in developing countries. However, with a few notable exceptions, it remains largely neglected as
an important public health problem. The purpose of this review is to provide an update on the current position of scabies with regard
to its complications and control in resource-poor countries.
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Epidemiology
The prevalence and complications of scabies make it a signifi-
cant public health problem in the developing world, with a
disproportionate burden in children living in poor, over-
crowded tropical areas [1,2]. The exact number of infected
cases worldwide is not known, but is estimated to be up to
300 million [3].
Exhaustive and complete data are not available from many
countries, but such data as can be utilized suggest that sca-
bies is endemic in tropical regions, with an average preva-
lence of 5–10% in children. A WHO review collated data
from 18 prevalence studies between 1971 and 2001, and
reported a scabies prevalence ranging between 0.2% and
24% [4]. Selected prevalence studies since 2001 are shown
in Table 1. It is notable that particularly high prevalence
figures have been reported in India, the South Pacific, and
northern Australia. For example, in a study of young people
in a rural Indian village, the prevalence of scabies was 70%
[5] In Australian Aboriginal communities, prevalence figures
of up to 50% have been reported, and studies in Fiji, Vanuatu
and the Solomon Islands have found the prevalence of sca-
bies in children to be 18.5%, 24%, and 25%, respectively, with
the prevalence being as high as 42% in one Fijian village [6,7].
In all regions, the burden of scabies is associated with
increased rates of pyoderma and complications of secondary
bacterial infection with group A streptococci and Staphylococ-
cus aureus [8]. For example, in Fiji, children with scabies
were 2.4 times more likely than children without scabies to
have active impetigo lesions [9].
A number of epidemiological factors have been proposed
as influencing the distribution of scabies infestation in popula-
tions, including: age, gender, ethnicity, overcrowding, hygiene,
and season. Scabies prevalence was previously thought to be
cyclical, but studies of long-term incidence suggest that epi-
demics and other observed fluctuations are multifactorial,
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being related to social and environmental changes such as
wartime, overcrowding, and climatic changes [10–14]. Ende-
mic rates in many tropical countries, without the significant
fluctuations reported elsewhere, suggest that the role of
herd immunity is likely to be more limited than previously
thought [15].
Whereas in developed nations the rates of infestation are
similar across age ranges [12], the highest rates in developing
countries are among preschool children to adolescents; rates
significantly decrease in mid-adulthood, and increase in the
elderly [13,16]. The attack rate is probably equal between
the sexes, and the differences in prevalence reported in
some studies are probably attributable to confounding fac-
tors [17]. Differences among racial groups have also been
described, and are probably attributable to socio-economic
and behavioural factors [10,17].
Overcrowding is an important factor in the spread of sca-
bies. Studies from Mali, India, Brazil and northern Australia
all show an association with overcrowding, especially sleeping
quarters [7,18–20]. Closed communities and institutional
environments experience high endemic rates and epidemic
outbreaks in tropical and developing countries. For example,
86% of children in a Sierra Leone displacement camp [21],
31% of children in a Malaysian welfare home [22] and 87% of
children in a Thai orphanage had scabies [23]. The role of
hygiene is controversial [24]; although poor hygiene has been
associated with high impetigo prevalence, and the use of
soap and water has been shown to reduce the prevalence of
impetigo [8,25], the available data suggest that hygiene is not
a significant factor for scabies infestation [26].
Overwhelmingly, the highest global rates of scabies are
seen in countries with hot, tropical climates [24]. However,
scabies is not limited to these regions. For example, studies
from Scotland and Israel demonstrated higher rates during
cooler seasons [11,27]; it has been suggested that this may
be related to increased human personal contact and over-
crowding, as well as increased mite survival and fertility in
cold weather [28,29], possibly because of microenvironmen-
tal conditions at the skin surface.
Crusted scabies is usually seen in immunocompromised
patients, especially in those with human immunodeficiency
virus infection, human T-lymphocytic virus 1 infection, or
medical immunosuppression, as well as in those with leprosy
and developmental disability, including Down syndrome.
However, there are reports of crusted scabies in those with
no identifiable immunodeficiency, especially Aboriginal Aus-
tralians [15,30,31].
Transmission
The transmission of scabies occurs with the burrowing of Sar-
coptes scabiei into the epidermis of the skin. Fertilized adult
female mites burrow into the stratum corneum, laying 0–4 eggs
per day for up to 6 weeks before dying. The entire develop-
mental life cycle, from egg to adult, involving three active inter-
mediate stages or instars, takes c. 2 weeks. However, classic
transmission studies have documented the first observation of
an adult female 3 weeks after initial colonization [32]. In pri-
mary infestations, an increase in S. scabiei numbers for up to
4 weeks has been reported, with a gradual reduction to c. 10–
12 mites as host immunity develops. In contrast, the severe
form of the disease, crusted scabies, is characterized by extre-
mely high mite burdens and severe crusting of the skin [33].
The most common source of transmission is prolonged
skin-to-skin contact with an infected individual (hand-holding,
sexual contact, etc.). It takes c. 15–20 min of close contact for
successful direct transmission, and for this reason scabies is
also considered to be a sexually transmitted disease. Intrafa-
milial transmission is frequently reported, and genotyping
results confirm long-held beliefs that transmission events for
S. scabiei tend to be localized in time or space, and that the
family/household is the focus of transmission [34,35]. How-
ever, cultural changes, such as the increasing use of institution-
TABLE 1. Prevalence studies of scabies in developing areas since 2004
Year Country Environment Ages Study area Diagnosis No of people seen Scabies (%) References
2005 Turkey Urban 4–6 years Preschool Clinical and
scrapings
1134 0.4 [102]
2005 Nigeria Rural 4–15 years School Clinical 1066 4.7 [103]
2005 Brazil Urban All ages Slum
Village
Clinical 1185
548
8.8
3.8
[20]
2007 Timor-Leste Rural All ages Four districts Clinical 1535 (245)a 17.3 (39.1)a [16]
2008 Nepal Rural All ages Village Clinical 878 4.7 [104]
2009 Malaysia Urban 13–17 years Boarding schools Clinical 944 8.1 [105]
2009 Brazil Rural All ages Village Clinical 1014 9.8 [106]
2009 Fiji Rural/urban 5–14 years Schools Clinical 3462 18.5 [9]
2010 Malaysia Urban Children Welfare home Clinical 120 31 [22]
aIn brackets - children < 10 years.
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alized care for the elderly and day care for the very young,
establish susceptible populations, and increasing institutional
outbreaks of scabies are now being reported in the literature.
Early classic studies proposed that it is the newly fertilized
adult female that is primarily responsible for transmission, as
up to 90% of immature mites die before reaching the adult
life stage [32,36]. An individual with a low parasite burden
can be cured by removal of only the adult females [37], and
Mellanby [36] was unable to establish an infestation by using
immature mites only. However, as the adult female rarely
leaves the burrow, the active, more immature, forms may be
responsible for transmission [38]. Infestations with high para-
site rates (>100 adult females) will have a proportionally
much greater number of developmental instars than adult
females, supporting the contention that the immature life-
cycle stage may be capable of transmission.
Blankets and clothing do not appear to be important in
transmission, and there is no conclusive evidence to suggest
that washing of clothing and blankets is necessary for the pre-
vention of spread. Live mites have been recovered from the
homes of scabetic patients [39]. The mite is an obligate para-
site and is highly susceptible to dehydration when off the host.
At temperatures below 20C, mites are almost immobile. Sig-
nificantly, in tropical conditions (30C and 75% relative humid-
ity), female mites have been shown to survive for 55–67 h off
the host [40], suggesting that, in these regions, fomites may be
a potential source of transmission. It is of note that eggs can
remain viable at low temperatures for up to 10 days off the
host, indicating that shed skin harbouring eggs is a potential
source of infestation. This is particularly pertinent in cases of
crusted scabies, where the patient’s surroundings are contami-
nated with shed epithelial debris containing all life stages. Ani-
mal scabies mites can sometimes infect humans, but these
infestations are self-limiting, and most cases and outbreaks of
scabies are caused by the human strain [35].
Pathogenesis
The pathogenesis of scabies involves many complex immuno-
logical and inflammatory pathways, some of which we are
only just beginning to understand. Skin inflammation, papules
and pruritus result from an immune-mediated antigen-specific
delayed hypersensitivity reaction. The initial 3–4 weeks after
the primary infestation are usually symptomless. In subse-
quent infestations, however, symptoms reappear much more
rapidly, in approximately 1–2 days. Mellanby, in an attempt
to re-infest patients who had been previously infected, was
successful with only 40% of his subjects, indicating the devel-
opment of protective immunity [35].
Two major forms of disease are recognized, ordinary and
severe crusted scabies, and are associated with protective
and pathological host responses, respectively. The different
clinical manifestations result from the type and magnitude of
the innate, cellular and humoral responses to mite proteins.
Some of the possible allergens potentially causing this
immune response have now been identified as a result of the
scabies gene discovery project [41]. Reports have now docu-
mented that patients with both crusted scabies and ordinary
scabies have strong cellular and humoral responses to multi-
ple S. scabiei homologues of house dust mite allergens [42].
Current data indicate that the protective immune response
in ordinary scabies is dominated by a Th1-type cytokine pro-
file associated with CD4+ T-lymphocytes, whereas the
severe form of crusted scabies is dominated by a non-
protective Th2 cytokine profile, and there is evidence that
the predominant effector cells in the skin may be CD8+ lym-
phocytes [43]. Analysis of cytokine levels showed that the
interferon-c/interleukin (IL)-4 ratio was significantly higher in
S. scabiei-stimulated peripheral blood mononuclear cells
(PBMCs) from ordinary scabies patients than in PBMCs from
crusted scabies patients, and increased levels of IL-5 and IL-
13 were observed in stimulated PBMCs from crusted scabies
as compared with PBMCs from ordinary scabies patients
[44]. Interestingly, PBMCs stimulated with scabies mite
extracts in healthy subjects showed increased production of
the regulatory cytokine IL-10. Accumulation of eosinophils
and production of total and specific IgE can be seen in both
forms, but are highly elevated in crusted scabies [45]. Mecha-
nisms of tissue damage in crusted scabies include direct cyto-
toxicity against keratinocytes, mostly mediated by CD8+ T-
cells, and release of cytokines, which amplify the inflamma-
tory response by targeting resident skin cells. The roles of
skin keratinocytes, eosinophils and basophils are not well
understood, but are likely to be critical to understanding the
evolution of the immune response in scabies.
Tissue-feeding parasites face significant dangers to their
early survival, owing to host innate immune responses. Scabies
mites feed on epidermal protein and host plasma, and are
exposed both internally and externally to host defence mecha-
nisms. Studies have found that uncharacterized mite proteins
have immunomodulatory properties that favour invasion of
the host by the parasite via downregulation or depression of
inflammatory processes of resident cells in the skin, and possi-
bly by influencing a delayed immune reaction [46]. Experi-
ments on human skin equivalents have demonstrated that
scabies mites can downregulate the expression of many cyto-
kines and adhesion molecules of skin epidermal keratinocytes,
dermal fibroblasts, and dermal microvascular endothelial cells
[47–49]. Complement has been shown to be an important
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component in host innate defence against ectoparasites, as
shown in blood-feeding ticks [50,51]. A scabies mite-binding
protein of gut origin (peritrophin) has been recently identified
within the mite gut as potentially binding to mannan-binding
lectin, and thus activating the lectin pathway of human comple-
ment activation [52]. Interestingly, with the identification of a
family of inactive multiple scabies mite homologues of the
group 3 serine protease allergens, a novel host immune eva-
sion strategy has been proposed for the scabies mite [41,53].
Two of these scabies mite-inactivated protease paralogues
were recombinantly expressed and shown to inhibit all three
pathways of the human complement system [54].
Another major subset of T-cells conprises the Th17 cells,
which are recognized as stimulating many cells of the innate
immune system; in particular, they recruit to and activate
neutrophils at sites of inflammation, and stimulate endothelial
and epithelial cells to synthesize the inflammatory cytokines
IL-1, IL-6, and tumour necrosis factor-a. Impairment of the
IL-17 pathway is associated with hyper-IgE syndrome [55],
whereas increased proliferation of Th17 cells is observed in
psoriatic plaques [56]. Preliminary findings of elevated IL-17
and IL-23 in crusted scabies are the first to indicate a contri-
bution of Th17-associated cytokines to a dysregulated
immune response in crusted scabies pathology (K. Mounsey,
personal communication).
Finally, the host-specific behaviour and transient nature of
cross-infestation on an unnatural host by scabies mites also
points towards possible factors beyond immunity in host pro-
tection and pathology. Physiological compatibility becomes
critical once a parasite makes intimate contact with a potential
host. Physiological compatibility is defined by the availability of
appropriate and sufficient nutrients and suitable physical,
chemical and immunological conditions for the parasite to
develop and reproduce. As well as digesting host proteins as a
food source, scabies mite proteases would facilitate the inva-
sion of host tissues, assisting in skin penetration and tissue
migration. Characterization of parasite excretory/secretory
products is vital for further understanding of host–parasite
relationships [57]. Emerging S. scabiei resistance to available
treatments and concerns about the effects of drug residues on
consumer health emphasize the need to develop effective anti-
parasite therapies. Improved understanding of scabies patho-
genesis will aid the development of vaccines or new
therapeutic treatments for susceptible populations.
Clinical Manifestations
Scabies remains one of the commonest of all skin diseases of
all ages in many regions in resource-poor societies, whereas
in industrialized societies its manifestations are different, and
the infection is most prevalent in specific groups, e.g. the
elderly living in institutions, such as nursing homes, or young
adults. The problem of scabies in resource-poor environ-
ments is compounded by the frequency of secondary infec-
tion by group A streptococci and staphylococci [58,59].
The clinical features of scabies follow the invasion of the
adult mite into the skin [60]. Itching, which may be very
severe and worse at night, is the predominant symptom. The
length of the incubation period after initial infection and
before symptoms first appear is variable, but it may take
14 days or more before itching is noticed. Classically, scabies
affects several skin sites, predominantly the hands between
the fingers, wrists, elbows, shoulders, genital area, including
the penis, lower legs, particularly the ankles, the scrotum in
males, and the breasts in women. Scratch marks are often
more widely distributed. The clinical signs are small (<5 mm)
papules or pustules, and small raised or flattened burrows,
which mark the course of the mite within the epidermis.
These are curved linear lesions that often end in a tiny pap-
ule or pustule, the site of the adult mite. These are often dif-
ficult to find, as they are often excoriated, but they are
easiest to see on the hands, fingers, wrists, and ankles. There
are often papules without obvious burrows on the external
genitalia. In light infestations, the best sites to examine for
lesions are the hands, fingers, and external genitalia. Usually,
the head is not affected, although it may be involved in
infants and babies, and, once again, itchy papules can be seen.
The other important clue to infection is the presence of
itching with or without a rash in other household members.
Usually, in tropical areas, several members of the family or
household are affected, often to strikingly different degrees,
with some patients showing fewer than four or five itchy
papules, and others being covered with papules and excoria-
tions.
Secondary infections are also common in the tropics, with
pustular lesions and crusted scales in the main affected areas
or over the face in children. These lesions may resemble
impetigo, and they are usually infected with group A strepto-
cocci or Staphylococcus aureus.
Late in some infections, larger, very itchy, papules or small
nodules, known as post-scabetic nodules, can be seen, and
are the result of a developing immune reaction to mite anti-
gens. Lesions are common in the genital area, and they may
also occur after treatment. In such cases, it is important to
screen for burrows, as these are the best sign that the infec-
tion remains active.
Other clinical variants include the crusted form of scabies,
also known as Norwegian scabies, which is seen in the
severely ill or immunocompromised. It has also been
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reported in Down’s syndrome. However, Human Immunode-
ficiency Virus-infected adults and children may show a similar
appearance. Here, the same areas are affected as in common
scabies, although there is less itching; other family members
are affected with the normal disease pattern. The clinical fea-
tures of crusted scabies are the appearance of dry scales and
crusts that are most marked over prominences such as the
dorsum of the fingers, wrists, and ears. The face may be
involved, and one or more nails show hyperkeratosis and
thickening. These crusted infections are caused by a superin-
fection with thousands of mites, and such patients are very
contagious.
Diagnosis
Clinical diagnosis remains the main method of disease ascer-
tainment in poor countries. It relies on identifying the pres-
ence of burrows in the skin, coupled with clinical features
such as the presence of itching in other members of the fam-
ily, itching that is worse at night, and the anatomical distribu-
tion of lesions. [61]. In communities in the tropics, normal
scabies may be hard to diagnose in every patient, as it has to
be distinguished from other causes of itching and papule for-
mation; in areas endemic for onchocerciasis, it is not easy to
separate acute papular onchodermatitis from scabies [62]. A
further diagnostic difficulty is that, often within a single fam-
ily, there is a range of disease severity, with lesions clustering
in older children in a few sites, perhaps just the hands,
whereas infants often have very widespread papular lesions,
including those affecting the scalp.
Confirmation of the diagnosis by direct tests, including the
demonstration of adult or immature scabies mites, ova or
even faeces in scrapings taken from a skin burrow, requires
both skill and perseverance. The technique uses direct
microscopy of material mounted in potassium hydroxide. It
remains a cheap but time-consuming option with a large
margin of diagnostic error. The use of the dermatoscope
[63] or PCR for diagnosis [64], or serodiagnosis [45], has
not been assessed in a tropical environment.
In most tropical areas, diagnosis depends on clinical recog-
nition, but for community-level diagnosis, simple clinically
based diagnostic algorithms have been advocated. The first
of these, developed in Mali, provides a degree of diagnostic
accuracy [65] This approach is based on a simple combina-
tion of symptoms and signs, and could be delivered after a
single day of training. A second algorithm, used in Fiji [66],
has also been shown to be useful in field settings. Both were
designed to aid the diagnosis of common skin diseases seen
in the local areas.
Complications
Whereas in many countries the main disabilities associated
with scabies, such as sleep loss, are caused by itching, the
disease in resource-poor settings is different, in that second-
ary infection brings a series of additional complications.
The best documented of these is the result of secondary
infection by group A streptococci [67]. For some time, it has
been recognized that infection with streptococci may result
in the development of glomerulonephritis [58]. This can be
detected with screening tests in a varying proportion of
those affected, mainly children. For instance, symptomatic
acute glomerulonephritis was reported in 10% of children in
a survey in northern Australia, but, in addition, 24% had
microscopic haematuria [68]. Thus, asymptomatic renal dam-
age can also occur. The infection was closely linked to skin
sores, and scabies was identified as the principal cause. Infec-
tion with streptococci can also occur in the absence of sca-
bies [69]. Acute post-streptococcal glomerulonephritis is
different in the tropics, as the skin, rather than the pharynx,
appears to be the main source of infection. It has also been
noted that persistent proteinuria can be detected for up to
16 years after the initial infection in 13% of those with rec-
ognized post-streptococcal glomerulonephritis vs. 4% of con-
trols in an area endemic for scabies-associated infection [70].
The real possibility exists that the renal damage that occurs
after a primary attack of scabies with secondary infection
may persist for years afterwards, with the potential to cause
long-term glomerular damage. A further study has shown
that control of scabies with ivermectin is also associated with
a significant reduction in both haematuria and isolation of
streptococci from skin lesions [71]. More information on the
frequency, geographical spread and chronic impact of these
renal complications, based on long-term scientific research,
is clearly needed.
A relationship between streptococcal infections secondary
to scabies and acute rheumatic fever has also been proposed
[2]. This is based on the observation that, in many areas
where rheumatic fever remains a significant problem in chil-
dren, the incidence of group A streptococcal throat infec-
tion, the traditional source of infection linked to rheumatic
fever, is low. By contrast, infection of the skin with group A
strains is common. There is, however, a paucity of group C
and group G streptococci linked to rheumatic fever, although
such strains may be identified in the throat in tropical areas.
It is therefore possible that the throat strains may exchange
virulence determinants with the more prevalent skin bacteria
and lead to rheumatic fever. Therefore, although the defini-
tive proof remains to be established, rheumatic fever remains
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a possible association with scabies-associated streptococcal
infections.
A further area where there is a possible link between sca-
bies and bacterial sepsis is in infant septicaemia caused by
Staphylococcus aureus [72]. The evidence is limited at present,
but an association between potentially fatal infant septicaemia
caused by Staphylococcus aureus and the presence of a skin
rash, possibly scabies, has been reported in the Gambia.
Not all of the complications of scabies are related to
infection, and household economic loss is also a problem in
resource-poor communities. A study in rural Mexico indi-
cated that families were spending a significant part of their
household income on ineffective treatment of scabies ($24)
over a 3-month period [73]. This had an impact on the fam-
ily’s ability to purchase other commodities, including food
for their families. Scabies in poor environments is therefore
both a potential cause of morbidity and a source of financial
burden, which compounds the impact of disease resulting
from this simple infection in poor communities.
Treatment
The incidence of scabies varies in a cyclical pattern with
time, although, in some communities, it is relatively static.
The reasons for this variation are unclear, but in resource-
poor settings any fall in incidence is inevitably followed by a
subsequent increase; in Guerrero state, Mexico [73], the
incidence of scabies cases has been through a trough, but is
beginning to rise once more. Treatment is therefore impor-
tant in all cases. Likewise, treatment should be given to all
household contacts, in order to prevent or contain spread.
The options for the treatment of scabies are summarized in
Table 2. Topical agents are considered to constitute first-line
treatment, with oral ivermectin generally being reserved for
recurrent, difficult-to-treat cases, or for patients with
crusted scabies; however, there is increasing interest in iver-
mectin for the treatment of simple scabies.
Topical agents
A number of topical agents are highly effective. Patients
should be given specific instructions about the use of topical
agents. The agent should be applied to the entire skin sur-
face, avoiding the eyes, mouth, and areas of non-intact skin,
for the period specified, and then completely washed off.
Application to the head is particularly important in children
and the elderly, who more commonly have lesions in the
scalp. Absorption is higher in infants and children, and the
agent should not be applied to warm or wet skin after a bath
[74,75]. Appropriate treatment for secondary bacterial
infection should also be given. There are no published data
on the efficacy of concurrent treatment of secondary bacte-
rial infection and scabies, but usually this is the most practical
approach to treatment in resource-poor communities. There
have been reports of serious adverse events (Table 2) with
lindane, permethrin, and crotamiton, but the causality is
unclear, and they appear to be confined to cases where
there is improper use of the products [4]. In developing
countries, the cheaper medications, such as sulphur prepara-
tions and benzyl benzoate, are often used. Sulphur-containing
preparations can also be used in infants and young children.
The rash and itch may persist for up to 2 weeks after a
successful treatment [76] Antihistamines can assist with itch-
ing. Causes of apparent treatment failure with an effective
regimen include incorrect diagnosis, dermatitis secondary to
the mite or topical agent, incorrect application of the topical
agent, poor penetration of hyperkeratotic skin or nails, re-
infestation from close contacts (especially those with crusted
lesions), and potential drug resistance [15].
Novel treatments, based on herbal compounds, have been
proposed, but comparisons with currently accepted treat-
ments are lacking [77]. Tea tree oil, eugenol compounds,
toto soap and lippie oil all show potential [78–81].
Oral agents
Ivermectin is the main oral agent used in scabies, although there
are other emerging agents, such as moxidectin, which have
shown success in the treatment of other parasitic infections.
Oral ivermectin has shown great promise in scabies treatment,
particularly for crusted scabies, institutional outbreaks, and
mass administration in highly endemic communities.
Efficacy
A review of randomized controlled trials by the Cochrane
Collaboration concluded that permethrin was the most effec-
tive agent for the treatment of scabies when treatment fail-
ure was used as the outcome measure [82]. The superiority
of permethrin includes comparison with ivermectin, although,
in one study, cure rates between ivermectin and permethrin
were similar when two doses of ivermectin were given
2 weeks apart (95% vs. 97.8%, respectively) [82]. Oral iver-
mectin has been found to be equally or more effective than
benzyl benzoate in four trials [83–87], although, in one
recent trial in Senegal, the study had to be stopped prema-
turely because of higher efficacy in the benzyl benzoate
group (68.8% cure) than in the ivermectin group (24.6%)
[88]; however, the trial has been criticized for a number of
reasons, including the dose of ivermectin used. Overall, there
has been considerable heterogeneity in the methods and
outcome measurements among treatment trials, and there is
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a need to standardize protocols for future trials, and, partic-
ular, to standardize the clinical assessment of scabies infesta-
tion.
Crusted scabies
No randomized controlled trials have compared treatment
regimens for patients with crusted scabies. Removal of the
crust is particularly important. Experience in northern Aus-
tralia suggests a regimen of multiple doses of oral ivermectin
with repeated topical permethrin and keratolytic therapy
[30,89].
Control of transmission, including environmental
decontamination
Treatment of close contacts, including recent sexual part-
ners, is recommended to prevent spread and re-infestation.
This is particularly important for mothers of infected infants.
Identification and treatment of ‘core transmitters’ with
crusted scabies is also important, because these patients
have extreme loads of parasites [90].
Living mites have been found in environmental dust sam-
ples on floors and furniture [91], particularly from patients
with crusted scabies [92]. However, early research by Mel-
lanby [36] demonstrated that transmission through bedding,
furniture and fomites is uncommon.
In resource-poor environments, treatment of bedding is
seldom practical.
Scabies can affect many mammals, including domestic dogs
and pigs, but the mites are genetically distinct, and cross-
infectivity is limited [35]. Successful control programmes,
without treatment of animals, suggest that resources should
be directed towards human control [6,93].
TABLE 2. Options for treatment of scabies
Drug Instructions for use [107] Notes
Topicala
Permethrin 5% Apply overnight (8–14 h),
and then wash off
In use since the 1980s.
The most expensive topical agent (up to ten times the cost of benzyl benzoate in some regions), but the most
widely used agent in developed countries
Generally well tolerated with few side effects
Treatment failures described with use of the 1% formulation (which should be used for head lice, not scabies).
There is increasing concern about potential resistance of the scabies mite to permethrin [107]
Permethrin is generally considered to be safe for younger children, but, owing to the theoretical risk of
neurological complications, some advocate a shorter application time in infants aged <2 months. In the USA,
oermethrin is only approved for infants aged >2 months
Permethrin is safe for use in pregnancy and lactation
Benzyl benzoate
10–25%
Leave on skin for 24 h
Dilute for use in children
and infants
In use since the 1930s
Availability and cost vary, but it is the most widely used agent in developing countries
Transient skin irritation and burning, immediately after application, is relatively common with the 25% lotion.
Neurological complications are possible with misuse
To reduce irritation, benzyl benzoate should be diluted to 12.5% for children and to 6.25% for infants, but this
reduces efficacy
Crotamiton 10% Apply for 24 h, and then
wash and reapply. Repeat
applications for 3–5 days
In use since the 1970s
It is a safe alternative for infants, but is less practical, as requires multiple treatments
Crotamiton is safe in pregnancy and lactation
Gamma benzene
hexachloride
(Lindane) 1%
Apply for 8 h, and then
wash off
In use since the 1940s
Lindane has been withdrawn from many countries, and is now a second-line treatment in developed countries.
It continues to be used in many tropical and developing countries, as it is cheap and effective
Systemic absorption is greater than for permethrin or crotamiton. There are several reports of aplastic
anaemia and neurological complications, including convulsions, which are more likely in cases of misuse [108].
The greatest risks are for infants, pregnant women, and those with neurological disorders
There is evidence of resistance and treatment failures with lindane [109]
Lindane should be avoided in infants, pregnant women, and lactating women
Malathion 0.5% Apply for 24 h In use since the 1970s
Has been used in the UK, but is infrequently used in other parts of the world
Sulphur ointment
6% (2–10%)
Apply for 24 h, and then
wash and reapply
Repeat applications for 3 days
Sulphur compounds have been used for centuries
The ointments are not recommended first-line agents, but are the only products available in some regions.
They been shown to be effective in outbreaks in regions without available alternatives
Precipitated ointments are often poorly accepted, as they are messy, malodorous, and cause skin irritation
Oral
Ivermectin 200 lg/kg orally
Repeat after 1–2 weeks
In use for mass treatment of onchocerciasis and filariasis since the late 1980s
Ivermectin is not approved for treatment of uncomplicated scabies in most countries (France and Brazil are
two notable exceptions)
Ivermectin has the additional benefit of treating multiple parasitic infections of the skin and digestive tract [110]
A report of increased risk of death among elderly patients taking ivermectin during an institutional outbreak of
scabies has not been replicated in other settings, and the causation of these results has been questioned[111]
Ivermectin is a substrate for the cytochrome P450 3A4 pathway, and so caution should be exercised in people
taking medications that induce or inhibit this pathway
Ivermectin has limited ovicidal activity, so repeat treatment is recommended
Further data are required regarding the use of ivermectin children of <15 kg and pregnant women; until these
data are available, ivermectin is not recommended for use in these groups
aAll treatments applied as a single application are likely to be more effective if repeated at 7–14 days, owing to the life cycle of the mite. Overtreatment should be avoided,
because of increased toxicity and local effects.
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Community control
In many developing countries, the Integrated Management of
Childhood Illness programme provides the backbone of clini-
cal care for primary healthcare workers by providing clinical
guidelines for the management of common childhood ill-
nesses.
Although the strategy of treating clinical cases and their
contacts undoubtedly provides relief for individuals with sca-
bies, there are few data that support its success in reducing
population prevalence in the longer term. Mass drug adminis-
tration, however, offers an alternative approach to popula-
tion control of scabies. Studies in scabies-endemic locations,
such as Panama and northern Australia, have shown that
mass treatment of highly endemic communities with topical
permethrin can substantially reduce scabies prevalence
[5,6,94–97]. Treatment of scabies alone also resulted in a sig-
nificant decrease in impetigo [98].
Oral ivermectin was used for mass treatment in the Solo-
mon Islands [71]. There was a considerable reduction in sca-
bies prevalence from 25% to 1%, with concomitant
reductions in impetigo and haematuria. A study from Papua
New Guinea also demonstrated decreased scabies preva-
lence after mass administration of ivermectin [99].
Factors in successful control include community involve-
ment and motivation, education, close follow-up, regular
re-screening, and prompt treatment of new cases [100]. Dif-
ficulties in sustaining a low prevalence have resulted from
low levels of treatment uptake of topical permethrin among
household contacts, and low motivation in some communi-
ties [101].
Conclusions
Scabies is a common disease that often dominates the pat-
tern of skin infection in developing countries, where it causes
both distress and discomfort to children and families. Largely
through poor management, families are forced to spend
much of their scarce money in trying to treat this infection.
Secondary bacterial infection is almost universal in this envi-
ronment, with potentially serious consequences for the indi-
vidual’s health. In recognition of its profound impact in the
poorest communities, it is now listed as a neglected tropical
disease by the PLoS Neglected Tropical Diseases Journal
(http://www.plosntds.org/static/scope.action). Action to con-
trol scabies in those countries where it has a significant
impact on public health should now be a priority. One of the
recurrent problems of this disease is that, in many parts of
the world, including Latin America and Ethiopia, there is a
close association between human louse infestations and
scabies, and control of both may be strategically linked with
ivermectin [20]. Further action aimed at achieving realistic
control targets should involve further research topics, such
as the long-term health consequences of scabies infection or
the explanation for cyclical incidence, as well as refining and
trialling appropriate regimens for community-based scabies
control using ivermectin and topical agents. In addition, we
need to establish an international alliance of partners, bring-
ing different skills, as well as influence, in order to make con-
trol a realistic and achievable goal.
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